Loading stock data…
CRIS
$0.43-0.02 (-4.63%)
Market OpenUpdated 3:07 PM EDT
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Curis, Inc. in the Healthcare sector is trading at $0.43 with a market capitalization of $19M. Wall Street consensus targets $14.00 (3 analysts), implying a +3183.3% move over the next 12 months. The stock is currently near its 52-week low of $0.42, remaining 60.1% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +3183.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0↓ | $1.14M↓ | $3.18M↑ | $2.75M↑ | $2.38M |
| Gross Profit | $0↓ | $1.14M↓ | $3.16M↑ | $2.73M↑ | $2.37M |
| Operating Income | -$11.52M↓ | -$7.57M↓ | -$6.92M↑ | -$8.25M↑ | -$10.16M |
| Net Income | -$24.20M↓ | $19.36M↑ | -$7.73M↑ | -$8.59M↑ | -$10.62M |
Peer Comparison
JNJUNHPFE
Fundamentals
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inh...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$19.49M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-166.56%
Volume
Today's trading volume
131,233
Recent News
Curis (CRIS) Q1 2026 Earnings Call Transcript
James Dentzer: Thank you, Diantha. As a reminder, the TakeAim Lymphoma study is a single-arm registrational study with an ORR endpoint that is evaluating emavusertib in combination with ibrutinib after a patient has progressed on BTKi therapy.
Curis, Inc. Q1 2026 Earnings Call Summary
Moby summary of Curis, Inc.'s Q1 2026 earnings call
Curis Inc (CRIS) Q1 2026 Earnings Call Highlights: Progress in Lymphoma Study and Financial ...
Curis Inc (CRIS) reports advancements in cancer studies and financial hurdles, with a focus on future growth and strategic developments.
Vericel Corporation (VCEL) Reports Q1 Loss, Beats Revenue Estimates
Vericel (VCEL) delivered earnings and revenue surprises of +17.24% and +7.25%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q1 Earnings and Revenue Estimates
Kiniksa Pharmaceuticals International, plc (KNSA) delivered earnings and revenue surprises of +50.00% and +5.24%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?